e0352 Efficacy and safety of aliskiren in chinese patients with mild or moderate essential hypertension
In: Heart, Jg. 96 (2010-10-01), S. A109- (2S.)
Online
unknown
Zugriff:
To assess the antihypertensive efficacy and safety of aliskiren compared with ramipril in Chinese patients with mild or moderate essential hypertension. Methods This is a double-blind randomised, multicenter, parallel group, active-controlled study. Following washout and single-blind placebo run-in period, 1147 patients with essential hypertension (mean sitting diastolic blood pressure [msDBP] ≥95 and 110 mm Hg) were randomised to receive either aliskiren 300 mg (n=288), 150 mg (n=284), 75mg (n=289) or ramipril 5 mg (n=286) for 8 weeks. Efficacy and safety were assessed at Week 2, 4 and 8 in treatment duration. Results 994 (86.7%) completed the study. At week 8, aliskiren therapy produced greater mean blood pressure reductions compared with ramipril therapy. All aliskiren dose groups were statistically non-inferior (p Conclusion Aliskiren was well tolerated, and superior or non-inferior to ramipril in lowering BP in Chinese patients with essential hypertension.
Titel: |
e0352 Efficacy and safety of aliskiren in chinese patients with mild or moderate essential hypertension
|
---|---|
Autor/in / Beteiligte Person: | Ningling, Sun ; Junren, Zhu |
Link: | |
Zeitschrift: | Heart, Jg. 96 (2010-10-01), S. A109- (2S.) |
Veröffentlichung: | BMJ, 2010 |
Medientyp: | unknown |
ISSN: | 1355-6037 (print) |
DOI: | 10.1136/hrt.2010.208967.352 |
Schlagwort: |
|
Sonstiges: |
|